Why Alternative Cancer Treatment

Contemporary Animal Experimentation

Part 2 of excerpts from A Critical Look at Animal Experimentation, ctd. from Part 1

Why Vivisection Persists

If animal experimentation is so flawed, why does it persist? There are several likely explanations.

Vivisection is easily published. In the "publish or perish" world of academic science, it requires little originality or insight to take an already well-defined animal model, change a variable or the species being used, and obtain "new" and "interesting" findings within a short period of time.

In contrast, clinical research, while directly applicable to humans, is often more difficult and time-consuming. Also, the many species available and the nearly infinite possible manipulations offer researchers the opportunity to "prove" almost any theory that serves their economic, professional, or political needs. For example, researchers have "proven" in animals that cigarettes both do and do not cause cancer — depending on the funding source.178,179

Vivisection is self-perpetuating. Scientists' salaries and professional status are often tied to grants, and a critical element of success in grant applications is proof of prior experience and expertise. Researchers trained in animal research techniques find it difficult or inconvenient to adopt new methods, such as tissue cultures.

Vivisection appears more "scientific" than clinical research. Researchers often assert that laboratory experiments are "controlled," because they can change one variable at a time. The control, however, is illusory. Any animal model differs in myriad ways from human physiology and pathology.

In addition, the laboratory setting itself creates confounding variables — for example, stress and undesired or unrecognized pathology in the animals. Such variables can have system-wide effects, skew experimental results, and undermine extrapolation of findings to humans.

Vivisection is lucrative. Its traditionally respected place in modern medicine results in secure financial support, which is often an integral component of a university's budget. Many medical centers receive tens of millions of dollars annually in direct grants for animal research, and tens of millions more for overhead costs that are supposedly related to that research.

Since these medical centers depend on this overhead for much of their administrative costs, construction, and building maintenance, they perpetuate vivisection by praising it in the media and to legislators.

Vivisection's morality is rarely questioned by researchers, who generally choose to dogmatically defend the practice rather than confront the obvious moral issues it raises.180-183 Animal re-searchers' language betrays their efforts to avoid morality. For example, they "sacrifice" animals rather than kill them, and they may note animal "distress," but they rarely acknowledge pain or other suffering.184 Young scientists quickly learn to adopt such a mindset from their superiors, as sociologist Arnold Arluke explains:

"One message — almost a warning — that newcomers got was that it was controversial or risky to admit to having ethical concerns, because to do so was tantamount to admitting that there really was something morally wrong with animal experimentation, thereby giving ‘ammunition to the enemy.’"184

Animal researchers' ethical defense of the practice has been superficial and self-serving. Usually, they simply point to supposed human benefits and argue that the ends justify the means.185,186 Often, they add that nonhuman animals are "inferior," lacking certain attributes compared to humans, such as intelligence, family structure, social bonding, communication skills, and altruism.

However, numerous nonhuman animals — among them rats, pigs, dogs, monkeys, and great apes — reason and/or display altruism. There is accumulating evidence that many animals experience the same range of emotions as humans.187-189 Chimpanzees and gorillas can be taught human sign language, and sign with one another even without humans present.190,191

The general public, which cares about animal welfare, has been led to believe that animals rarely suffer in laboratories. Animal researchers often cite U.S. Department of Agriculture (USDA) statistics (derived from researchers themselves) that only 6 to 8 percent of animals used in vivisection experience pain unrelieved by anesthesia or analgesia.192

However, the 2002 Helms’ Amendment ensures that mice, rats, and birds, which constitute over 90% of all animals used in vivisection in the United States, receive absolutely no protection from the Animal Welfare Act.193

Furthermore, evidence indicates that many animal researchers fail to acknowledge — or even perceive — animal pain and suffering. For example, sociologist Mary Phillips observed animal researchers kill rats in acute toxicity tests, induce cancer in rodents, subject animals to major surgery with no post-operative analgesia, and perform numerous other painful procedures without administering anesthesia or analgesia to the animals.

Nevertheless, in their annual reports to the USDA, none of the researchers acknowledged that any animals had experienced unrelieved pain or distress. Phillips reported, "Over and over, researchers assured me that in their laboratories, animals were never hurt. . . 'Pain' meant the acute pain of surgery on conscious animals, and almost nothing else. . . [When I asked] about psychological or emotional suffering, many researchers were at a loss to answer."194

The tens of millions of animals used and killed each year in American laboratories generally suffer enormously, often from fear and physical pain, nearly always from the deprivation inflicted by their confinement, which denies their most basic psychological and physical needs.


The value of animal experimentation has been grossly exaggerated by those with a vested economic interest in its preservation. Because animal experimentation focuses on artificially created pathology, involves confounding variables, and is undermined by differences in human and nonhuman anatomy, physiology, and pathology, it is an inherently unsound method to investigate human disease processes.

The billions of dollars invested annually in animal research would be put to much more efficient, effective, and humane use if redirected to clinical and epidemiological research and public health programs.

Purchase Information:

This booklet costs .50 each, .30 in quantities of 10 or more, and can be obtained by contacting MRMC by e-mail (stkaufman at mindspring.com), or by contacting MRMC at:

Medical Research Modernization Committee
P.O. Box 201791
Cleveland, Ohio 44120
tel./fax 216-283-6702

[Above contact data and purchasing options may be outdated, pls check at their website www.mrmcmed.org for up-to-date information.)

References and Notes

  1. The Physicians Committee for Responsible Medicine and the Medical Research Modernization Committee combined have over 4500 scientist and physician members, most of whom are highly critical of vivisection.
  2. Barnard ND, Kaufman SR. Animal research is wasteful and misleading. Scientific American 1997; Feb:80-82.
  3. Mukerjee M. Trends in animal research. Scientific American 1997; Feb:86- 93.
  4. Loeb JM, Hendee WR, Smith SJ, Schwartz R. Human vs animal rights. In defense of animal research. Journal of the AMA 1989;262:2716-2720.
  5. Botting JH, Morrison AD. Animal research is vital to medicine. Scientific American 1997; Feb:83-85.
  6. Reines BP. On the locus of medical discovery. Journal of Medicine and Philosophy 1991;116:183-209.
  7. Reines BP. On the role of clinical anomaly in Harvey's discovery of the mechanism of the pulse. Perspectives in Biology and Medicine 1990;34:128- 133.
  8. McQuarrie I. The Experiments of Nature and Other Essays from the Porter Lectures. Lawrence, Kansas, University of Kansas Press, 1944.
  9. Peller S. Quantitative Research in Human Biology and Medicine. Bristol, England, John Wright & Sons, 1967.
  10. Beeson PB. The growth of knowledge about a disease: hepatitis. American Journal of Medicine 1979:67;366-370.
  11. Good RA. Runestones in immunology. Journal of Immunology 1976; 117:1413-1428.
  12. Good RA. Keystones. Journal of Clinical Investigation 1968;47:1466-1471. Beeson and Good have recently emphasized that they do not oppose animal experimentation, and they consider it important to medical progress. However, their own articles speak for themselves.
  13. Greek CR, Greek JW. Sacred Cows and Golden Geese. New York, Continuum, 2000.
  14. Greek CR, Greek JW. Specious Science. New York, Continuum, 2002.
  15. Brecher R. The Consumers Union Report on Smoking and the Public Interest. Mount Vernon, Consumers Union, 1963.
  16. Doll R, HillAB, The mortality of doctors in relation to their smoking habits: A preliminary report. British Medical Journal 1954;1:1451-1455.
  17. Northrup E. Men, mice, and smoking, in Science Looks at Smoking. New York, Coward-McCann, 1957, p 133.
  18. Enterline PE. Asbestos and cancer, in Gordis L (ed). Epidemiology & Health Risk Assessment. New York, Oxford Univ Pr, 1988.
  19. Gardner MJ, Snee MP, Hall AJ, et al. Results of case-control study of leukaemia and lymphoma among young people near Sellafield nuclear plant in West Cumbria. British Medical Journal 1990;300:423-429.
  20. Wald ML. Pioneer in radiation sees risk even in small doses. New York Times Dec 8, 1994, p A1.
  21. Stewart A. Alternative sources of risk estimates for cancer effects of radiation. The Mount Sinai Journal of Medicine 1995;62:380-385.
  22. Gould JM, Sternglass EJ. Nuclear fallout, low birthweight, and immune deficiency. International Journal of Health Science 1994;24:311-335.
  23. Bross ID. Fifty Years of Folly and Fraud "In the Name of Science." Buffalo, Biomedical Metatechnology, 1994.
  24. Ainley CC, Senapati A, Brown IM, et al. Is alcohol hepatotoxic in the baboon? Journal of Hepatology 1988;7:85-92.
  25. Paul JR. History of Poliomyelitis. New Haven, Yale Univ. Press, 1971.
  26. Sabin AB. Statement of Albert B. Sabin, M.D. Hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs of the House of Representatives, April 26, 1984, serial no 98-48.
  27. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science 1949;109:85-86.
  28. Domingo RT, Fries C, Sawyer P, Wesolowski S. Peripheral arterial recon- struction. Transplantation of autologous veins. Transactions of the American Society of Artificial Internal Organs 1963;9:305-316.
  29. Hume D. Experiences with Renal Homotransplantation in the Human Subject. Journal of Clinical Investigation 1955;34:327-381.
  30. American Medical Association Council on Scientific Affairs. Animals in research. Journal of the AMA 1989;261:3602-3606.
  31. Bailar JC III, Gornik HL. Cancer undefeated. New England Journal of Medicine 1997;336:1569-1574.
  32. Beardsley T. A war not won. Scientific American 1994:270(1);130-138.
  33. Jamal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer Journal for Clinicians 2002;52:23-47.
  34. US General Accounting Office. Cancer Patient Survival: What Progress has been Made? Washington, DC, General Accounting Office, 1987.
  35. Dulbecco R. A turning point in cancer research: Sequencing the human genome. Science 1986;231:1055-1056.
  36. Leavitt J. The case for understanding the molecular nature of cancer: Some recent findings and their implications. Medical News Sept 9, 1985.
  37. BrossI. Crimes of Official Science. Buffalo, Biomedical Metatechnology, 1987.
  38. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-467.
  39. GardnerMB, Luciw PA. Animal Models of AIDS. FASEB Journal 1989;3:2593-2606.
  40. Nath BM, Schumann KE, Boyer JD. The chimpanzee and other non- human-primate models in HIV-1 vaccine research. Trends in Microbiology 2000;8:426-431.
  41. Stott J, Almond N. Assessing animal models of AIDS. Nature Medicine 1995;1:295-297.
  42. Shortcomings of AIDS-Related Animal Experimentation. New York, Medical Research Modernization Committee, 1996.
  43. Wyand MS. The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Research and Human Retroviruses 1992;8:349-356.
  44. Johnston MI. The role of nonhuman primate models in AIDS vaccine development. Molecular Medicine Today 2000;6:267-270.
  45. DeVita VT Jr., Hellman S, Rosenberg SA. AIDS Etiology, Diagnosis, Treatment, and Prevention, 3rd Edition. Philadelphia, JB Lippincott, 1992.
  46. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'deoxythymidine (BS A509U). Proceedings of the National Academy of Sciences USA 1985;82:7096-7100.
  47. Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH 189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapeutics 1991;35:1386-1390.
  48. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990:248;358-361.
  49. Giannelli MA. Three blind mice, see how they run: A critique of behavioral re- search with animals, in Fox MW, Mickley LD (eds). Advances in Animal Welfare Science 1985/86. Washington DC, Humane Society of the US, 1985, pp 109-164.
  50. Cohen MJ. The irrelevance of animal experimentation in modern psychiatry and psychology, in Cohen MJ, Natelson N (eds) Facing the Challenge. Alexandria VA, Concern for Helping Animals in Israel, 1991, pp 91-107.
  51. Cohen MJ. Animal testing. Psychiatric News [letter]. Nov 20, 1987.
  52. Bannister D. The fallacy of animal experimentation in psychology, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981, pp 307-317.
    53. Bannister D. The myth of physiological psychology. Bulletin of the British Psychological Society 1968;21:229-231.
  53. Shapiro K. Animal Models of Human Psychology: Critique of Science, Ethics and Policy. Seattle, Hogrefe & Huber, 1997.
  54. Plous S. Attitudes towards the use of animals in psychological research and education: Results from a national survey of psychologists. American Psychologist 1996;51:1167-1180.
  55. Bowlby J. Maternal care and mental health. Geneva, WHO Monograph Series, No. 2, 1952.
  56. Spitz RA, Wolf KM. Anaclitic depression. Psychoanalytic Studies of the Child 1946;2:313-342.
  57. Cohen MJ. A critique of the use of maternally deprived monkeys to study alcohol abuse. MRMC Report 1996;9(1):1-2.
  58. Cohen MJ. A critique of maternal deprivation monkey experiments at The State University of New York Health Science Center. MRMC Report 1996;9(4):1-8.
  59. Dole VP. On the relevance of animal models to alcoholism in humans. Alcoholism Clinical and Experimental Research 1986;10:361-363.
  60. Kelly JA. Psychological research and the rights of animals: Disagreement with Miller [letter]. American Psychologist 1986;41:839-841.
  61. Lee T. Gene Future. New York, Plenum Pr, 1993, p 177.
  62. Clarke LL, Grubb BR, Gabriel SE, Smithes O, Koller BH, Boucher RC. Defective epithelial transport in a gene-targeted mouse model of cystic fibrosis. Science 1992;257:1125-1128.
  63. Zbinden G, Flury-Roversi M. Significance of the LD50 test for the toxicological evaluation of chemical substances. Archives of Toxicology 1981:47;77-99.
  64. Fano A. Lethal Laws: Animal Testing, Human Health and Environmental Policy. London, Zed Books, 1997, pp 157-159.
  65. Stephens M. Replacing animal experiments, in Langley G (ed). Animal Experimentation: The Consensus Changes. New York, Chapman and Hall, 1989, pp 144-168.
  66. Clemedson C, McFarlane-Abdulla E, Andersson M, et al. MEIC evaluation of acute systemic toxicity. Alternatives to Laboratory Animals 1996;24 (suppl 1):273-311
  67. Shrivastava R. In vitro tests in pharmacotoxicology. Alternatives to Laboratory Animals 1997;25:339-340.
  68. Sharpe R. The Draize test — motivations for change. Food and Chemical Toxicology 1985;23:139-143.
  69. Freeberg FE, Hooker DT, Griffith JF. Correlation of animal eye test data with human experience for household products: An update. Journal of Toxicology-Cutaneous & Ocular Toxicology 1986;5:115-123.
  70. Langley G, Fisher G. New Perspectives in Cosmetic Toxicology: Non-animal Tier-Testing Strategies. London, International Fund for Animal Welfare, 1995.
  71. Abelson PH. Diet and cancer in humans and rodents. Science 1992;255:141.
  72. Salsburg D. The lifetime feeding study of mice and rats — an examination of its validity as a bioassay for human carcinogens. Fundamental and Applied Toxicology 1983;3:63-67.
  73. Lave LB, Ennever FK, Rosenkranz HS, Omenn GS. Information value of the rodent bioassay. Nature 1988;336:631-633.
  74. Worth AP, Balls M (eds). Alternative (Non-animal) Methods for Chemical Testing: Current Status and Future Prospects. ATLA 2002;30 (suppl 1):83- 93.
  75. Fawver AL, Branch CE, Trentham L, Robertson BT, Beckett SD. A comparison of interactive videodisc instruction with live animal laboratories. American Journal of Physiology 1990:259 (Adv Physiol Educ 4); S11-S14.
  76. Hepner LA. Animals in Education. Albuquerque, NM, Richmond Pub, 1994.
  77. McGregor JC. The use of the placenta for microsurgical vascular practice. Journal of the Royal College of Surgeons 1980;25:233-236.
  78. Ota D, Loftin B, Saito T, Lea R, Keller J. Virtual reality in surgical education. Computers in Biology & Medicine 1995;25:127-137. See also www.meti.com.
  79. LaFollette H, Shanks N. Animal models in biomedical research: Some epistemological worries. Public Affairs Quarterly 1992;7:113-130.
  80. LaFollette H, Shanks N. Brute Science. New York, Routledge, 1997.
  81. Kaufman SR, Reines BP, Casele H, Lawson L, Lurie J. An evaluation of ten randomly chosen animal models of human diseases. Perspectives on Animal Research 1989;1(Suppl):1-128.
  82. Kaufman SR, Czarnecki T, Haralabatos I, Richardson M. Animal models of degenerative neurological diseases. Perspectives on Medical Research 1991;3:9-48.
  83. Smith CD. A critique of brain wound research. Perspectives on Animal Research 1989;1:19-24.
  84. Buyukmihci NC. Response to Dr. Blakemore's assertion that work involving nonhuman animals has led to significantly greater understanding and treatment of amblyopia. Perspectives on Animal Research 1989;1:57-62.
  85. Cohen MJ, Black DN, Fouts RS, Dobbs FW. A critique of neurology experiments at Northwestern University. Perspectives on Medical Research 1993;4:22-28.
  86. Kaufman SR. Animal models of spinal cord injury. Perspectives on Medical Research 1990;2:1-12.
  87. Mack JD, Greenberg RA. Review of scoliosis research at the University of Michigan. Perspectives on Medical Research 1990;2:33-36.
  88. Committee on Animal Models in Biomedical Research. Aping Science. New York, MRMC, 1995.
  89. Barnard N, Hou S. Inherent stress: The tough life in lab routine. Lab Animal Sept 1988, pp 21-27.
  90. Cotton P. Animals and science benefit from "replace, reduce, refine" effort. Journal of the AMA 1993;270:2906.
  91. Hewitt HB. The use of animals in experimental cancer research, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981.
  92. Freedman DA, Zeisel H. From mouse to man: The quantitative assessment of cancer risks. Statistical Science 1988;3:3-28.
  93. Smith CD. Head injury research at the University of Cincinnati. Perspectives on Animal Research 1989;1:9-18.
  94. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990;249:970-971.
  95. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: Are they relevant to human disease? Stroke 1990;21:1-3.
  96. Habal MB. The influence of lip repair with and without soft-tissue under-mining on facial growth in beagles [discussion]. Plastic and Reconstructive Surgery 1988;82:756-759.
  97. Fernandes D. Animal experimentation: Necessary or not? Cleft Palate Journal 1989;26:258.
  98. Wiebers DO, Adams HP, Whisnant JP. Relevance of animal models to stroke [letter]. Stroke 1990;21:1091-1092.
  99. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-354.
  100. Sacco, RL, DeRosa JT, Haley Jr EC, et al. Glycine antagonist in neuro protection for patients with acute stroke. Journal of the American Medical Association 2001;285:1719-1728.
  101. Sharpe R. Science on Trial. Sheffield, England, Awareness Pub,1994.
  102. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. New England Journal of Medicine 1991;325:1468-1475.
  103. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995;333:1099-1105.
  104. Kolata G. 2 top diet drugs are recalled amid reports of heart defects. New York Times Sept 16, 1997, p A1.
  105. Stolberg SG. New information on gene patient's death fails to resolve mystery. New York Times, December 2, 1999.
  106. General Accounting Office. FDA Drug Review: Postapproval Risks 1976-1985. Washington, DC, GAO, 1990.
  107. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association 2002;287:2215-2220.
  108. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. Journal of the American Medical Association 1998;279:1200-1205.
  109. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science, 1990;249: 1007-1011.
  110. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nature Medicine 1996;2:1184-1185.
  111. Berardesca E, Maibach IH. Racial differences in sodium lauryl sulphate induced cutaneous irritation: Black and White. Contact Dermatitis 1988;18:65-70.
  112. Kaufman SR. Does vivisection pass the utilitarian test? Public Affairs Quarterly 1995;9:127-137.
  113. Barber B. The ethics of experimentation with human subjects. Scientific American 1976;234(2):25-31.
  114. Kiernan V. Radiation doctors abused trust in the name of science. New Scientist Oct 14, 1995, p 8.
  115. Annas GJ. Baby Fae: The "anything goes" school of human experimentation. Hastings Center Report 1985;15(1):15-17.
  116. Preston R. The Hot Zone. New York, Random House, 1994.
  117. Cohen MJ. Ebola Alice? TexasRepublic 1996;3(2):27-30.
  118. McKenna MAJ. Monkey virus kills Yerkes researcher. Atlanta Journal- Constitution Dec 12, 1997.
  119. Pennisi E. Monkey virus DNA found in rare human cancers. Science 1997;275:748-749.
  120. Baboon cells fail to combat AIDS. Nature 1996;379:577.
  121. Hooper. E. The River: A Journey to the Source of HIV and AIDS. Boston, Little, Brown & Co, 1999.
  122. Reinhardt V, Roberts A. The African polio vaccine-acquired immune deficiency syndrome connection. Medical Hypotheses 1997;48:367-374.
  123. Horowitz LG. Emerging Viruses: AIDS and Ebola. Rockport, Mass, Tetrahedron, 1996.
  124. Allan JS. Xenotransplantation at a crossroads: Prevention versus progress. Nature Medicine 1996:2:18-21.
  125. Fano A, Cohen MJ, Cramer M, Greek R, Kaufman SR. Of Pigs, Primates and Plagues: A Layperson's Guide to the Problems with Animal-to-Human Organ Transplants. New York, Medical Research Modernization Committee, 1997.
  126. LeTissier P, Stoye JP, Takeuchi Y, Patience C, Weiss RA. Two sets of human-tropic pig retrovirus. Nature 1987;389:681-682.
  127. Kimbrell A. The Human Body Shop. San Francisco, HarperCollins, 1994, pp 183-187.
  128. Rhodes R. Deadly Feasts. New York, Simon & Schuster, 1997.
  129. Epstein SS. Unlabeled milk from cows treated with biosynthetic growth hormones: A case of regulatory abdication. International Journal of Health Services 1996;26:173-185.
  130. Epstein SS. A needless new risk of breast cancer. Los Angeles Times March 20, 1994.
  131. Challcombe DN, Wheeler EE. Safety of milk from cows treated with bovine somatotropin. Lancet 1994;344:815-816.
  132. Cummins R. An international boycott of genetically engineered foods. Pure Food Campaign, Washington, DC, March 4, 1997.
  133. Leonard RE. Codex at the crossroads: Conflict on trade health. Nutrition Week 1995;25:4-5.
  134. Heimlich HJ, Patrick EA. The Heimlich maneuver: Best technique for saving any choking victim's life. Postgraduate Medicine 1990;87:68-79.
  135. Cohen MJ, Young C. "Alcoholic" Rats and Other Alcohol Research Using Animals. New York, National Research Information Center, 1989.
  136. Sitaram N, Gershon S. Animal models to clinical testing — promises and pitfalls. Progress in Neuropsychopharmacology Biology and Psychiatry 1983;7:227-228.
  137. Davis JM. Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry, Fourth Ed. Baltimore, William and Wilkins, 1985.
  138. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. Circulation 1991;83:356-362.
  139. Zaridze D, Maximovitch D, Zemlyanaya G, Aitakov ZN, Boffetta P. Exposure to environmental tobacco smoke and risk of lung cancer in non- smoking women from Moscow, Russia. International Journal of Cancer 1998;75:335-338.
  140. Lower GM. Human carcinogenesis: A disciplinary perspective. Medical Hypotheses 1990;33:1-6.
  141. Ornish D, for the Multicenter Lifestyle Demonstration Project Research Group. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project. American Journal of Cardiology 1998;82:72T-76T.
  142. Esselstyn Jr. CB. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease. American Journal of Cardiology 1999;84:339-341.
  143. Zaridze D, Maximovitch D, Zemlyanaya G, Aitokov ZN, Boffetta P. Exposure to environmental tobacco smoke and risk of lung cancer in non-smoking women from Moscow, Russia. International Journal of Cancer 1998;75:335-338.
  144. Heimlich HJ. Advantages and safety of clinical research, in Cohen M, Natelson N (eds). Facing the Challenge. Alexandria, VA, CHAI, 1990, pp 123-135.
  145. Pechura CM, Martin JB (eds). Mapping the Brain and Its Functions. Washington DC, National Academy Press, 1991.
  146. Savoy RL. History and future directions of human brain mapping and functional neuroimaging. Acta Psychologica 2001;107:9-42.
  147. Taylor-Robinson SD. Applications of magnetic resonance spectroscopy to chronic liver disease. Clinical Medicine 2001;1:54-60.
  148. Schmermund A, Baumgart D, Erbel R. Coronary calcification by electron beam tomography: comparison with coronary risk factors and angiography. Journal of Cardiovascular Risk 2000;7:99-106.
  149. Hill RB, Anderson RE. The Autopsy: Medical Practice and Public Policy. Boston, Butterworth, 1988.
  150. Kaufman SR. Autopsy: A crucial component of human clinical investigation. Archives of Pathology and Laboratory Medicine 1996;120:767-770.
  151. Opie EL. Disease of the Pancreas. Philadelphia, JB Lippincott, 1910.
  152. Barron M. The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis. Surgery, Gynecology and Obstetrics 1920;31:437-448.
  153. Ahnen DJ. Are animal models of colon cancer relevant to human disease. Digestive Diseases & Sciences 1985;30(12 Suppl):103S-106S.
  154. Pories SE, Ramchurren N, Summerhayes I, Steele G. Animal models for colon carcinogenesis. Archives of Surgery 1993;128:647-653.
  155. Lasagna L (ed). Postmarketing Surveillance of Multisource Drugs. Boston, Center for the Study of Drug Development, 1986.
  156. van Boxtel CJ, Wang G. Some observations on pharmacoepidemiology in Europe. Netherlands Journal of Medicine 1997;51:205-212.
  157. Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer 1949;2:943-945.
  158. Boesen E. Cytotoxic Drugs in the Treatment of Cancer. London, Edward Arnold, 1969, p 24.
  159. Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate 1893;8:278-286.
  160. Caldwell A. Origins of Psychopharmacology: From CPZ to LSD. Springfield, Charles C Thomas, 1970.
  161. Lehmann HE, KlineNS. Clinical discoveries with antidepressant drugs, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 209-221.
  162. Sulser F, Mishra R. The discovery of tricyclic antidepressants and their mode of action, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 233-247.
  163. Stevens C. Statement before the House Subcommittee on Labor, Health, and Human Services, April 30, 1987.
  164. Pihl A. UICC Study Group on chemosensitivity testing of human tumors. Problems — applications — future prospects. International Journal of Cancer 1986;37:1-5.
  165. Gura T. Systems for identifying new drugs are often faulty. Science 1997;278:1041-1042.
  166. Anon. Drug discovery screen adapts to change. Journal of the National Cancer Institute 1990;82:1087.
  167. Waldren C, Correll L, Sognier MA, Puck TT. Measurement of low levels of x-ray mutagenesis in relation to human disease. Proceedings of the National Academy of SciencesUSA 1986;83:4839-4843.
  168. Hayflick L. The choice of the cell substrate for human virus vaccine pro- duction. Laboratory Practice 1970;19:58-62.
  169. Beale AJ. Use of tissue cultures for testing vaccines. Journal of the Royal Society of Medicine 1978;71:681-686.
  170. Hayflick L. Human virus vaccines: Why monkey cells? Science 1972;176:183-184.
  171. Hendriksen CFM. Laboratory Animals in Vaccine Production and Control: Replacement, Reduction and Refinement. Boston, Kluwer Academic Pub, 1988.
  172. Metz B, Hendricksen CF, Jiskoot W, Kersten GF. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine 2002;20:2411-30.
  173. Hendriksen C, Rozing J, van der Kamp M, de Leeuw W. The production of monoclonal antibodies: Are animals still needed? Alternatives to Laboratory Animals 1996;24:109-110.
  174. Bross ID. Mathematical models vs. animal models. Perspectives on Animal Research 1989;1:83-108.
  175. Blumenson L, Bross I. A mathematical analysis of the growth and spread of breast cancer. Biometrics 1969;25:95-109.
  176. Bazell RJ. Smoking dogs: Tobacco institute tries to discount cancer studies. Science 1970;170:515.
  177. Auerbach O, Hammond EC, Kirmian D, Garfinkel L. Effects of cigarette smoking on dogs II. Pulmonary neoplasms. Archives of Environmental Health 1970;21:754-768.
  178. Gluck JP, Kubacki SR. Animals in biomedical research: The undermining effect of the rhetoric of the besieged. Ethics and Behavior 1991;2:157-173.
  179. Weibers DO, Leaning J, White RG. Animal protection and medical science. The Lancet 1994;343:902-904.
  180. Kaufman SR. [letter]. The Lancet 1994;343:1574.
  181. Dunayer J. Censored: Faculty who oppose vivisection. Z Magazine 1993; April;57-60.
  182. Arluke A. The ethical socialization of animal researchers. Lab Animal June 1994, pp 30-35.
  183. Rowan AN. Is justification of animal research necessary? [letter]. Journal of the AMA 1993;269:1113-1114.
  184. Buyukmihci NC. Consistency in treatment and moral concern. Journal of the American Veterinary Medical Association 1995;206:477-480.
  185. Masson JM, McCarthy S. When Elephants Weep: The Emotional Lives of Animals. New York, Delacorte Pr, 1995.
  186. Griffin DR. Animal Minds. Chicago, Univ Chicago Pr, 1992.
  187. Bekoff M. The Smile of a Dolphin. New York, Discovery Books, 2000.
  188. Fouts RS. Next of Kin. New York, William Morrow, 1997.
  189. Patterson F, Linden E. The Education of Koko. New York, Rinehart & Winston, 1991.
  190. AMA White Paper. Use of Animals in Biomedical Research: The Challenge and Response. American Medical Association, 1988.
  191. U.S. Department of Agriculture. 2002 Farm Bill Amendment Section on Rats, Mice, and Birds. www.aphis.usda.gov/ac/farmbill2002.html.
  192. Phillips M. Savages, drunks and lab animals: The researcher's perception of pain. Society and Animals 1993:1;61-81.

The above excerpts are from

A Critical Look at Animal Experimentation
by Christopher Anderegg, M.D., Ph.D.
Murry J. Cohen, M.D.
Stephen R. Kaufman, M.D.
Rhoda Ruttenberg, M.D.
Alix Fano, M.A.

Sixth Edition

Medical Research Modernization Committee
Modernizing Medical Research and Promoting Human Health

Table of Contents
Historical Impact of Animal Experimentation
Contemporary Animal Experimentation
Selective Diseases
Degenerative Neurological Diseases
Psychiatry and Psychology
Genetic Diseases
Toxicity Testing
Educational Exercise
Animal Research Risks
Importance of Clinical Research
Non-Animal Methodologies
Patient Studies
Post-Marketing Surveillance
Other Non-Animal Methods
References and Notes

The entire document is also available as a PDF file.

The MRMC is a nonprofit health advocacy organization composed of scientists and medical professionals who identify and promote efficient, reliable, and cost-effective research methods. The MRMC focuses exclusively on the scientific merits of different research approaches, even though some undoubtedly raise serious and important ethical concerns.

Sponsored Links

Related sections


Copyright © 2004-2024 healingcancernaturally.com and respective authors.
Unauthorized republishing of content is strictly forbidden. Each and every breach of copyright will be pursued to the fullest extent of the law.
Use of this site signifies your agreement to the disclaimer.